Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | OTC | P00480 | 1/20 | 0.49 |
| ▸ | NOS2 | P35228 | 7/20 | 0.47 |
| ▸ | NOS1 | P29475 | 6/20 | 0.47 |
| ▸ | NOS3 | P29474 | 4/20 | 0.47 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GSR | P00390 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL6468370 | 1.00 | PMP22 (0.50) | PMP22OTCNOS2NOS1NOS3 | |
| Arginine SCHEMBL17874428 | 1.00 | PMP22 (0.50) | PMP22OTCNOS2NOS1NOS3 | |
| Arginine SCHEMBL17874429 | 1.00 | PMP22 (0.50) | PMP22OTCNOS2NOS1NOS3 | |
| Arginine SCHEMBL27809411 | 0.95 | ALOX15 (0.50) | PMP22OTCNOS2NOS1NOS3 | |
| Arginine SCHEMBL247132 | 0.95 | ALOX15 (0.50) | PMP22OTCNOS2NOS1NOS3 | |
| Arginine SCHEMBL247131 | 0.95 | ALOX15 (0.50) | PMP22OTCNOS2NOS1NOS3 | |
| Arginine SCHEMBL30883903 | 0.94 | OTC (0.49) | PMP22OTCNOS2NOS1NOS3 | |
| Arginine SCHEMBL28180160 | 0.94 | OTC (0.49) | PMP22OTCNOS2NOS1NOS3 | |
| Arginine SCHEMBL29020068 | 0.94 | OTC (0.49) | PMP22OTCNOS2NOS1NOS3 | |
| Arginine SCHEMBL17874430 | 0.93 | GSR (0.56) | PMP22OTCNOS2NOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180256717-A1 | PROTEIN COMPOSITIONS AND USE THEREOF | DRUG DISCOVERY LABORATORY AS (NO) | 2018-09-13 | — | — | US | disclosed |
| EP-3236942-A1 | PROTEIN COMPOSITIONS AND USE THEREOF | Drug Discovery Laboratory AS (NO) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016103034-A1 | PROTEIN COMPOSITIONS AND USE THEREOF | DRUG DISCOVERY LABORATORY AS (NO) | 2016-06-30 | — | — | WO | disclosed |
| US-20050119275-A1 | Salt and crystal forms of (5-chloro-2-{2-[4-(4-fluoro-benzyl)-(2R,5S)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-methanesulfonic acid | PFIZER INC. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119275-A1 | Salt and crystal forms of (5-chloro-2-{2-[4-(4-fluoro-benzyl)-(2R,5S)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-methanesulfonic acid | CCR1, CCR6, CCR3 | PMP22 969/4885OTC 4515/4885NOS2 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.